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Bronchopulmonary mucoepidermoid carcinoma (MEC) ac-counts for less than 1% of lung tumors. All age groups are
affected, but 50% of these cases occur in patients younger
than 30 years. Chemotherapy has demonstrated limited suc-
cess in treating this rare condition. Responses to the epider-
mal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI) gefitinib has been reported in patients with recurrent
metastatic bronchopulmonary MEC.1,2 We report a case of
bronchopulmonary MEC responding to treatment using the
EGFR TKI, erlotinib.
CASE REPORT
A 35-year-old Chinese male patient presented with a
mediastinal tumor with no nodal or distant metastases on
positron emission tomography-computed tomography (CT)
scan. He received excision of the anterior mediastinal tumor
with en-bloc wedge resection of the bilateral upper lobes of
lung (Figure 1). Pathological review showed a 5 cm  12
cm  11 cm, high-grade MEC, with no nodal involvement.
He received adjuvant radiotherapy for involved adventitial
margins. Inoperable local recurrence with superior vena cava
(SVC) obstruction was detected by contrast CT scan 1 year
later. He declined systemic treatment for 4 months from
diagnosis but received SVC stent insertion and pacemaker
insertion for complete heart block and congestive heart fail-
ure secondary to malignant tumor infiltration of bilateral atria
and right ventricular outflow tract.
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FIGURE 1. The core biopsy of the resected surgical speci-
men at 100 magnification, with the intermediate cells
showing squamoid features with small to large mucus-filled
vacuoles (left). The mucin stain highlights the mucin in the
cytoplasm (right).
FIGURE 2. The vertical profile of the scans corresponds to
the same timeframe, with the column on the left showing
disease status before treatment of erlotinib and column on
the right showing treatment response to erlotinib. The pri-
mary mediastinal tumor recurrence with superior vena cava
stent occlusion, the lung metastases, and pleural metastases
show partial response (a), the pleural effusion and pleural
metastases show complete response (b), and the splenic me-
tastases show partial response (c).
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A contrast CT scan at 4 months from recurrence
showed occlusion of the SVC stent, pericardial effusion,
bilateral lung and pleural metastases, left pleural effusion,
and splenic metastasis. Erlotinib was initiated empirically,
without EGFR mutational analysis. A chest radiograph taken
2 weeks after treatment initiation showed disease response.
The patient experienced complications of grade 3 acneiform
rash, grade 2 hand-foot syndrome, and warfarin overdose
upon clinical review at 4 weeks. Therapeutic level of antico-
agulation was achieved by dose reduction in warfarin, and the
skin complications were managed by topical therapy. A
contrast CT scan at 6 weeks of treatment showed at least
partial response in all disease sites (Figure 2).
The patient presented with prehospital cardiac arrest 8
weeks after treatment. A retrospective analysis of the EGFR
mutational status by direct sequencing performed on the
resected surgical specimen was negative.
DISCUSSION
This is the third case report that has demonstrated
clinical responses of bronchopulmonary MEC to EGFR TKI
in the absence of a sensitizing EGFR mutation. 30 to 40% of
patients with EGFR wild-type non-small cell lung cancer
(NSCLC) develop stable disease after EGFR TKI therapy.
Two phase III trials examining erlotinib in EGFR wild-type
NSCLC has demonstrated improved survival when compared
with placebo.3,4
In vitro studies employing salivary MEC and NSCLC
cell lines have shown that 38 to 81% of salivary MECs harbor
a t(11;19) translocation resulting in the CRTC1-MAML2
fusion oncogene. This fusion protein is also present in bron-
chopulmonary MEC and induces a 20-fold expression in
amphiregulin.5 Amphiregulin upregulation predicts tumor
growth inhibition by gefitinib in EGFR wild-type NSCLC
cell lines in vitro. Subject to further investigations in the
clinical setting, CRTC-MAML2 oncogene may be a feasible
target for EGFR TKI therapy, expanding the scope of treat-
ment with these agents beyond EGFR-sensitizing mutations.
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